drugset / Trial / NCT05281094

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT05281094

Phase 2/3 Terminated 3084 enrolled HilleVax
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo. The study will enroll 3000 children who will be 5 months of age at the time of the first dose study vaccine. The second dose of study vaccine will be given 28 days after the first dose.

Timeline

Start
2022-04-28
Primary completion
2023-12-28
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HIL-214 Vaccine Intramuscular

Indications